---
title: "Drug developer Seaport Therapeutics seeks up to $212M in US IPO"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284219616.md"
description: "Seaport Therapeutics (SPTX) has filed for an IPO to raise up to $212M by offering 11.8M shares priced between $16 and $18 each. The company, focused on developing oral therapies for neuropsychiatric diseases, aims for a market value of $912M at the top share price. Goldman Sachs, JP Morgan, and Leerink Partners are leading the offering. Seaport reported a net loss of $74.9M last year and is backed by PureTech Health, which owns nearly 50% of the company."
datetime: "2026-04-27T12:51:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284219616.md)
  - [en](https://longbridge.com/en/news/284219616.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284219616.md)
---

# Drug developer Seaport Therapeutics seeks up to $212M in US IPO

Seaport Therapeutics (SPTX) on Monday filed for an initial public offering of 11.8M shares priced between $16 and $18 each, seeking to raise as much as about $212M. At $18 per share, the clinical-stage biotech firm will have a market value of $912M. The company has applied to list its shares on the Nasdaq Global Market under the ticker SPTX. Goldma...

### Related Stocks

- [PRTC.US](https://longbridge.com/en/quote/PRTC.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PRTCY.US](https://longbridge.com/en/quote/PRTCY.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)

## Related News & Research

- [BUZZ-Apogee Therapeutics reports results from mid-stage skin disease therapy; shares fall](https://longbridge.com/en/news/287766012.md)
- [<![CDATA[Pharmaceutical Executive Daily: CVS Health to Offer Zepbound and Foundayo]]>](https://longbridge.com/en/news/287960347.md)
- [CORRECTED-Sanofi’s Venglustat Granted Priority Review By The FDA For Treatment Of GD3 (May 28)](https://longbridge.com/en/news/288053971.md)
- [BUZZ-Outlook Therapeutics jumps on plans to resubmit marketing application for eye disease treatment](https://longbridge.com/en/news/287634369.md)
- [Apogee secures up to $1.3 billion from Blackstone to advance eczema drug](https://longbridge.com/en/news/287810224.md)